AUPH EBITDA | Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (AUPH) EBITDA

2026-06-30: Basis Reported; EBITDA $51.17M*; Operating income $46.34M; Depreciation and amortization $4.83M*.
2026-03-31: Basis Reported; EBITDA $46.24M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $38.1M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $34.61M*; Operating income $29.75M; Depreciation and amortization $4.87M*.

Complete source-backed ebitda history.

Available history: 2020-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$51.17M*	$46.34M	$4.83M*	$83.22M	61.49%*	(m)	$52.57M*	(m)	$13.05M	(m)	$11.37M
2026-03-31	Reported	$46.24M	(m)	(m)	(m)	59.50%	(m)	$32.56M	(m)	$7.47M	(m)	$9.57M
2025-12-31	Reported	$38.1M	(m)	(m)	(m)	49.41%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$34.61M*	$29.75M	$4.87M*	$73.47M	47.11%*	(m)	$44.45M*	(m)	$8.44M	(m)	$411.00K
2025-06-30	Reported	$24.95M*	$20.08M	$4.86M*	$70.01M	35.63%*	(m)	$44.24M*	(m)	$7.43M	(m)	$643.00K
2025-03-31	Reported	$26.7M	(m)	(m)	(m)	42.75%	(m)	$1.30M	(m)	$5.74M	(m)	$1.00M
2024-12-31	Reported	$3.19M	(m)	(m)	(m)	5.33%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$16.64M*	$11.75M	$4.89M*	$67.77M	24.55%*	(m)	$17.03M*	(m)	$3.05M	(m)	$457.00K
2024-06-30	Reported	$3.33M*	-$1.51M	$4.84M*	$57.19M	5.82%*	(m)	$15.84M*	(m)	$4.08M	(m)	$756.00K
2024-03-31	Reported	-$8.41M	(m)	(m)	(m)	-16.71%	(m)	-$18.60M	(m)	$5.55M	(m)	$739.00K
2023-12-31	Reported	(m)	-$29.67M	(m)	$45.09M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	(m)	-$16.26M	(m)	$54.52M	(m)	(m)	-$13.28M*	(m)	$13.61M	(m)	$298.00K
2023-06-30	Reported	(m)	-$16.17M	(m)	$41.49M	(m)	(m)	-$2.83M*	(m)	$12.65M	(m)	-$642.00K
2023-03-31	Reported	(m)	-$29.58M	(m)	$34.41M	(m)	(m)	-$31.67M	(m)	$13.16M	(m)	$436.00K
2022-12-31	Reported	(m)	-$28.10M	(m)	$28.43M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	(m)	-$9.50M	(m)	$55.78M	(m)	(m)	-$15.36M*	(m)	$10.97M	(m)	$954.00K
2022-06-30	Reported	(m)	-$35.99M	(m)	$28.19M	(m)	(m)	-$27.87M*	(m)	$11.53M	(m)	$9.00K
2022-03-31	Reported	(m)	-$37.88M	(m)	$21.63M	(m)	(m)	-$46.75M	(m)	$12.62M	(m)	$10.00K
2021-12-31	Reported	(m)	-$32.70M	(m)	$23.40M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	(m)	-$50.35M	(m)	$14.67M	(m)	(m)	-$40.25M*	(m)	$20.07M	(m)	$8.00K
2021-06-30	Reported	(m)	-$47.13M	(m)	$6.62M	(m)	(m)	-$37.98M*	(m)	$10.09M	(m)	$18.00K
2021-03-31	Reported	(m)	-$50.54M	(m)	$914.00K	(m)	(m)	-$53.54M	(m)	$9.83M	(m)	$8.00K
2020-12-31	Reported	(m)	-$8.05M	(m)	$50.03M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	(m)	-$42.31M	(m)	$29.00K	(m)	(m)	-$28.42M*	(m)	$12.24M	(m)	-$15.00K
2020-06-30	Reported	(m)	-$26.86M	(m)	$29.00K	(m)	(m)	-$22.04M*	(m)	$11.08M	(m)	$2.00K
2020-03-31	Reported	(m)	-$27.06M	(m)	$30.00K	(m)	(m)	-$22.61M	(m)	$13.84M	(m)	-$238.00K
2019-12-31	Reported	(m)	-$34.84M	(m)	$29.00K	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	(m)	-$24.07M	(m)	$230.00K	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Reported	(m)	-$17.14M	(m)	$29.00K	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Reported	(m)	-$14.89M	(m)	$30.00K	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Rolling	(m)	$150.75M*	(m)	$311.51M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2026-03-31	Rolling	(m)	$124.49M*	(m)	$298.30M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-12-31	Reported	$124.36M	(m)	(m)	(m)	43.94%	(m)	$135.66M	(m)	$32.51M	(m)	-$173.04M
2025-12-31	Rolling	(m)	$104.91M*	(m)	$283.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Rolling	(m)	$70.01M*	(m)	$265.81M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-06-30	Rolling	(m)	$52.01M*	(m)	$260.11M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-03-31	Rolling	(m)	$30.41M*	(m)	$247.29M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-12-31	Reported	$14.76M	(m)	(m)	(m)	6.28%	(m)	$44.39M	(m)	$20.79M	(m)	$1.70M
2024-12-31	Rolling	(m)	-$4.69M*	(m)	$235.13M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Rolling	(m)	-$32.69M*	(m)	$220.36M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-06-30	Rolling	(m)	-$60.70M*	(m)	$207.10M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-03-31	Rolling	(m)	-$75.36M*	(m)	$191.41M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-12-31	Reported	-$80.04M	(m)	(m)	(m)	-45.61%	(m)	-$33.46M	(m)	$49.64M	$195.00M	$551.00K
2023-12-31	Rolling	(m)	-$91.69M*	(m)	$175.51M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Rolling	(m)	-$90.12M*	(m)	$158.85M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-06-30	Rolling	(m)	-$83.35M*	(m)	$160.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-03-31	Rolling	(m)	-$103.17M*	(m)	$146.81M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-12-31	Reported	-$108.76M	(m)	(m)	(m)	-81.15%	(m)	-$79.53M	(m)	$44.99M	$196.40M	$1.83M
2022-12-31	Rolling	(m)	-$111.47M*	(m)	$134.03M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Rolling	(m)	-$116.08M*	(m)	$129.00M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-06-30	Rolling	(m)	-$156.93M*	(m)	$87.89M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-03-31	Rolling	(m)	-$168.07M*	(m)	$66.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-12-31	Reported	-$177.97M	(m)	(m)	(m)	-390.25%	(m)	-$157.69M	(m)	$51.14M	$173.50M	$760.00K
2021-12-31	Rolling	(m)	-$180.74M*	(m)	$45.60M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Rolling	(m)	-$156.08M*	(m)	$72.23M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$148.04M*	(m)	$57.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$127.77M*	(m)	$51.00M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$102.92M	(m)	(m)	(m)	-205.35%	(m)	-$69.86M	(m)	$50.33M	$97.30M	-$94.00K
2020-12-31	Rolling	(m)	-$104.29M*	(m)	$50.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$131.08M*	(m)	$117.00K*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$112.83M*	(m)	$318.00K*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$103.11M*	(m)	$318.00K*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	(m)	-$90.94M	(m)	$318.00K	(m)	(m)	-$63.59M	(m)	$52.87M	$22.30M	$144.00K
2019-12-31	Rolling	(m)	-$90.94M*	(m)	$318.00K*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	(m)	-$55.24M	(m)	$463.00K	(m)	(m)	-$51.61M	(m)	$41.38M	(m)	$73.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Zai Lab Ltd (ZLAB)		$2.241B	-113.34
Prestige Consumer Healthcare Inc. (PBH)	United States	$2.163B	13.03
OCULAR THERAPEUTIX, INC (OCUL)	United States	$2.159B	-7.15
Bausch Health Companies Inc. (BHC)		$2.113B	-1.68
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
Viridian Therapeutics, Inc.\DE (VRDN)	United States	$2.342B	-5.38
Mineralys Therapeutics, Inc. (MLYS)	United States	$2.353B	-6.82
Generate Biomedicines, Inc. (GENB)	United States	$2.052B